NEWS RELEASE
FOR IMMEDIATE RELEASE

VITAL SIGNS, INC. ANNOUNCES A 21% INCREASE IN
QUARTERLY EARNINGS FROM CONTINUING OPERATIONS

     TOTOWA, N.J., May 8, 2007 -- VITAL SIGNS, INC. (NASDAQ: VITL) today announced sales and earnings for the second quarter ended March 31, 2007.

     Income from continuing operations increased 21% to $8,781,000, for the second quarter of fiscal 2007 compared to $7,252,000 for the second quarter of fiscal 2006. Earnings from continuing operations per diluted share increased 18% to $.66 per share for the second quarter of fiscal 2007 compared to $.56 per share for the second quarter of fiscal 2006.

     Net revenues for the second quarter of fiscal 2007 increased 6.5% to $50,393,000 compared to $47,298,000 in the comparable period last year.

     Following are the net revenues by business segment for the second quarter of fiscal 2007 compared to the second quarter of fiscal 2006 (in thousands of dollars):

	NET REVENUES BY BUSINESS SEGMENT
	FOR THE THREE MONTHS ENDED MARCH 31,
	2007	2006	PERCENT CHANGE
Anesthesia	$  18,869	$  18,410	2.5	%
Respiratory/Critical Care	11,961	10,960	9.1	%
Sleep	12,612	11,632	8.4	%
Interventional cardiology/radiology	6,951	6,296	10.4	%
Net Revenues	$  50,393	$  47,298	6.5	%

     Terry Wall, President and CEO of Vital Signs, commented, “I am pleased with this quarter’s 21% earnings growth as it reflects the progress of our lean manufacturing initiatives. These projects have resulted in a gross margin improvement of 1.5%, primarily in our Anesthesia segment. Additionally, we are continuing to expand our in in-house manufacturing of non-latex breathing bags, which will continue to generate cost savings for ’07 and ‘08. I am also pleased with the 9.1% growth of our Respiratory/Critical Care segment which was especially rewarding after a period of low growth.”

     For the six month period ended March 31, 2007 income from continuing operations increased 19.5% to $16,281,000 as compared to $13,626,000 for the comparable fiscal 2006 period. Diluted earnings per share from continuing operations increased 16.0% to $1.23 for the six month period ended March 31, 2007 compared to $1.06 for the six month period ended March 31, 2006.

     Net revenues for the first six months of fiscal 2007 increased 6.2% to $96,055,000 as compared to $90,436,000 in the comparable period last year.

     Following are the net revenues by business segment for the six months ended March 31, 2007 and 2006 (in thousands of dollars):

	NET REVENUES BY BUSINESS SEGMENT
	FOR THE SIX MONTHS ENDED MARCH 31,
	2007	2006	PERCENT CHANGE
Anesthesia	$   36,577	$  35,578	2.8	%
Respiratory/Critical Care	23,281	21,505	8.3	%
Sleep	23,358	21,807	7.1	%
Interventional cardiology/radiology	12,839	11,546	11.2	%
Net Revenues	$  96,055	$  90,436	6.2	%

Mr. Wall added: “Our guidance for fully diluted earnings per share from continuing operations for fiscal 2007, has been adjusted to between $2.59 and $2.67 per share (GAAP), to reflect Pharma Tech becoming a discontinued operation in the first quarter of fiscal 2007.”

Net cash provided from continuing operations for the six months ended March 31, 2007 was approximately $18.9 million as compared to net cash used of $11.8 million for the six months ended March 31, 2006.

     On May 7, 2007 the Board approved an increase in the quarterly dividend to $0.10 per share payable on May 31, 2007 to shareholders of record on May 18, 2007.

     All non-historical statements in this press release, including Vital Signs’ guidance with respect to fully diluted earnings per share from continuing operations for fiscal 2007, constitute Forward Looking Statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements as a result of a variety of risks and uncertainties, including unanticipated delays in bringing products to market, regulatory approval of new products, market conditions, and competitive responses as well as other factors referred to by Vital Signs in its Annual Report on Form 10-K for the year ended September 30, 2006.

     Vital Signs, Inc. and its subsidiaries design, manufacture and market primarily single-use medical products for the anesthesia, respiratory/critical care, achieving the number one market share position in the U.S. for five of its major product categories. Vital Signs also provides diagnostic services and therapeutic devices for the treatment of obstructive sleep apnea. Vital Signs is ISO 13485 certified and has CE Mark approval for its products. In 2006, Forbes Magazine named Vital Signs, Inc. as one of the “200 Best Small Companies in America” based on financial criteria.

VITL-G

FOR FURTHER INFORMATION, CONTACT:	Terry D. Wall, President
	or William Craig, CFO
	(973) 790-1330
	http://www.vital-signs.com

VITAL SIGNS, INC.
FINANCIAL HIGHLIGHTS
STATEMENT OF INCOME

(In Thousands, Except Per Share Amounts)
(Unaudited)

		THREE MONTHS ENDED						SIX MONTHS ENDED
		MARCH 31,						MARCH 31,
		2007			2006			2007			2006
Gross revenues	$	69,303		$	64,205		$	132,672		$	123,536
Rebates		(17,673	)		(15,704	)		(34,260	)		(30,837	)
Other deductions		(1,237	)		(1,203	)		(2,357	)		(2,263	)
Net revenues		50,393			47,298			96,055			90,436
Cost of goods sold and services
provided		23,337			22,628			44,917			43,156
Gross Profit		27,056			24,670			51,138			47,280
Expenses:
Selling, general and administrative		12,721			12,418			24,627			24,083
Research and development		1,727			1,739			3,572			3,397
Restructuring charge		—			—			—			—
Interest and other (income)/expense, net		(955	)		(652	)		(1,779	)		(1,241	)
Income from continuing operations
Before income taxes and minority interest		13,563			11,165			24,718			21,041
Provision for income taxes		4,528			3,725			7,941			7,043
Income from continuing operations before
minority interest		9,035			7,440			16,777			13,998
Minority interest		254			188			496			372
Income from continuing operations		8,781			7,252			16,281			13,626
(Loss) Income from discontinued operations,
net		(180	)		216			(386	)		502
Net income	$	8,601		$	7,468		$	15,895		$	14,128
Earnings (loss) per common share:
Basic:
Income per share from continuing
operations	$	0.66		$	0.56		$	1.23		$	1.07
Discontinued operations		(0.01	)		0.02			(0.03	)		0.04
Net earnings	$	0.65		$	0.58		$	1.20		$	1.11
Diluted:
Income per share from continuing
operations	$	0.66		$	0.56		$	1.23		$	1.06
Discontinued operations		(0.01	)		0.02			(0.03	)		0.04
Net earnings	$	0.65		$	0.58		$	1.20		$	1.10
Basic weighted average number of shares		13,220			12,898			13,219			12,743
Diluted weighted average number of shares		13,255			13,001			13,271			12,840

VITAL SIGNS, INC.
FINANCIAL HIGHLIGHTS

BALANCE SHEET HIGHLIGHTS:

	(In Thousands)
	(Unaudited)
	March 31,
		2007		2006
Cash and cash equivalents	$	56,458	$	20,732
Short Term Investments		81,943		87,158
Accounts Receivable		33,324		26,984
Inventory		20,747		19,387
Current Assets		215,077		178,916
Total Assets	$	321,601	$	284,872
Current Liabilities	$	14,957	$	14,919
Total Liabilities		14,957		14,919
Shareholders equity	$	301,462	$	265,806